Is Vertex Stock Still a Good Buy?
Over the past ten years or so, Vertex Pharmaceuticals (NASDAQ:…
Sell
42
ALEC Quote, Financials, Valuation and Earnings
Last price:
$1.12
Seasonality move
:
14.09%
Day range:
$1.12 - $1.18
52-week range:
$0.87 - $6.78
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
1.09x
P/B ratio:
0.88x
Volume:
373K
Avg. volume:
707.4K
1-year change:
-78.52%
Market cap:
$112M
Revenue:
$100.6M
EPS (TTM):
-$1.23
Analysts' Opinion
-
Consensus RatingAlector has received a consensus rating of Buy. The company's average rating is a Buy based on 5 Buy ratings, 1 Hold rating, and 1 Sell rating.
-
Price Target UpsideAccording to analysts' consensus price target of $4.22, Alector has an estimated upside of 273.7% from its current price of $1.13.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $1.00 representing 100% downside risk from its current price of $1.13.
Fair Value
-
According to the consensus of 7 analysts, Alector has 273.7% upside to fair value with a price target of $4.22 per share.
ALEC vs. S&P 500
-
Over the past 5 trading days, Alector has overperformed the S&P 500 by 0.41% suggesting its relative strength compared to the major market average is strong at this time.
Share Buyback
-
Alector does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Alector has grown year-over-year revenues for 2 quarters straight. In the most recent quarter Alector reported revenues of $54.2M.
Earnings Growth
-
Alector has grown year-over-year earnings for 0 quarters straight. In the most recent quarter Alector reported earnings per share of -$0.02.
Enterprise value:
-292M
EV / Invested capital:
--
Price / LTM sales:
1.09x
EV / EBIT:
--
EV / Revenue:
-2.90x
PEG ratio (5yr expected):
-1.71x
EV / Free cash flow:
1.26x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
--
Return On Assets:
-21.17%
Net Income Margin (TTM):
-118.39%
Return On Equity:
-83.91%
Return On Invested Capital:
-82.82%
Operating Margin:
-13.37%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2023-12-31 | 2024-12-31 | |
| Income Statement | ||||||
| Revenue | $133.6M | $97.1M | $100.6M | $15.2M | $54.2M | |
| Gross Profit | -- | -- | -- | -- | -- | |
| Operating Income | -$137.8M | -$151.7M | -$145M | -$47.5M | -$7.2M | |
| EBITDA | -$129.4M | -$142.9M | -$136.2M | -$45.2M | -$5.2M | |
| Diluted EPS | -$1.61 | -$1.55 | -$1.23 | -$0.49 | -$0.02 | |
| Period Ending | 2020-12-31 | 2021-12-31 | 2022-12-31 | 2023-12-31 | 2024-12-31 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $421.5M | $749.7M | $726.4M | $565.8M | $424.8M | |
| Total Assets | $488.3M | $814.7M | $787.6M | $621.8M | $468.3M | |
| Current Liabilities | $68.1M | $139.6M | $93.8M | $177.9M | $125.1M | |
| Total Liabilities | $220.7M | $513.9M | $573.2M | $487.7M | $341.5M | |
| Total Equity | $267.5M | $300.7M | $214.4M | $134.2M | $126.8M | |
| Total Debt | -- | -- | -- | -- | $9.4M | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2023-12-31 | 2024-12-31 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$20.3M | -$184.2M | -$229.9M | -$46.1M | -$55M | |
| Cash From Investing | -$159M | $101.9M | $107.1M | $18.1M | $41.4M | |
| Cash From Financing | $4.5M | $2.6M | $81.5M | $590K | $9.8M | |
| Free Cash Flow | -$24.4M | -$186.5M | -$231.2M | -$46.3M | -$55.2M | |
ALEC
Sector
Market Cap
$112M
$34.9M
Price % of 52-Week High
16.67%
44.35%
Dividend Yield
0%
0%
Shareholder Yield
-38.97%
-0.82%
1-Year Price Total Return
-78.52%
-38.5%
Beta (5-Year)
0.736
0.738
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Buy
Level
$1.10
200-day SMA
Sell
Level
$3.36
Bollinger Bands (100)
Sell
Level
1.23 - 1.99
Chaikin Money Flow
Sell
Level
-26.7M
20-day SMA
Buy
Level
$1.05
Relative Strength Index (RSI14)
Sell
Level
48.40
ADX Line
Buy
Level
19.55
Williams %R
Neutral
Level
-29.7297
50-day SMA
Sell
Level
$1.32
MACD (12, 26)
Sell
Level
-0.05
25-day Aroon Oscillator
Sell
Level
-44
On Balance Volume
Neutral
Level
40.3M
Financial Scores
Sell
Altman Z-Score
(Annual)
Level (-2.1886)
Sell
CA Score
(Annual)
Level (-2.7891)
--
Beneish M-Score
(Annual)
Level (--)
Sell
Momentum Score
Level (1)
Sell
Ohlson Score
Level (2.6184)
--
Piotroski F Score
(Annual)
Level (--)
--
Quality Ratio Score
Level (--)
Sell
Fundamental Score
Level (2)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Alector Inc is a clinical-stage biopharmaceutical company. It is engaged in developing a novel therapeutic approach for the treatment of neurodegeneration. The firm is involved in developing therapies that are designed to simultaneously counteract pathologies by restoring healthy immune function to the brain. Its pipeline products include AL001, AL002, AL003, and AL101.
Stock Forecast FAQ
In the current month, ALEC has received 5 Buy ratings 1 Hold ratings, and 1 Sell ratings. The ALEC average analyst price target in the past 3 months is $4.22.
-
Where Will Alector Stock Be In 1 Year?
According to analysts, the consensus estimate is that Alector share price will rise to $4.22 per share over the next 12 months.
-
What Do Analysts Say About Alector?
Analysts are divided on their view about Alector share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Alector is a Sell and believe this share price will drop from its current level to $1.00.
-
What Is Alector's Price Target?
The price target for Alector over the next 1-year time period is forecast to be $4.22 according to 7 Wall Street analysts, 5 of them rate the stock a Buy, 1 rates the stock a Sell, and 1 analyst rates the stock a Hold.
-
Is ALEC A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Alector is a Buy. 5 of 7 analysts rate the stock a Buy at this time.
-
How Can I Buy Shares Of ALEC?
You can purchase shares of Alector via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, tastytrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Alector shares.
-
What Is The Alector Share Price Today?
Alector was last trading at $1.12 per share. This represents the most recent stock quote for Alector. Yesterday, Alector closed at $1.13 per share.
-
How To Buy Alector Stock Online?
In order to purchase Alector stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is Okta Stock Finally Gaining Investor Confidence?
Given how digital transformation has proliferated, cyberattacks have also been…
Is The Trade Desk the Best Advertising Stock Now?
The worldly backdrop is now shrouded in heavy uncertainty and…
Stock Ideas
Buy
59
Is AAPL Stock a Buy?
Market Cap: $3.2T
P/E Ratio: 35x
Buy
58
Is MSFT Stock a Buy?
Market Cap: $2.9T
P/E Ratio: 33x
Buy
55
Is NVDA Stock a Buy?
Market Cap: $2.7T
P/E Ratio: 37x
Alerts
Buy
85
HIMS alert for Apr 30
Hims & Hers Health [HIMS] is down 5.02% over the past day.
Buy
54
EAT alert for Apr 30
Brinker International [EAT] is down 2.48% over the past day.
Sell
16
NSP alert for Apr 30
Insperity [NSP] is down 5.61% over the past day.
